Novel targeted therapies for advanced esophageal cancer

Diseases of the Esophagus

Volumn 20, Issue 5, 2007, Pages 365-371

  Lin, C C ^a,b   Papadopoulos, Kyri P ^c,d,e  

^a CTRC Institute for Drug Development   (United States)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^c South Texas Accelerated Research Therapeutics   (United States)

^d UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^e NONE   (United States)

Author keywords

Angiogenesis inhibitor; Cyclin dependent kinase; Epidermal growth factor; Monoclonal; Protein kinase inhibitor

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; BEVACIZUMAB; BORTEZOMIB; BRYOSTATIN; CAPECITABINE; CARBOPLATIN; CETUXIMAB; CISPLATIN; CYCLIN DEPENDENT KINASE; DEPSIPEPTIDE; DNA METHYLTRANSFERASE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ERLOTINIB; FLAVOPIRIDOL; FLUOROURACIL; FOLINIC ACID; GEFITINIB; HISTONE DEACETYLASE; IRINOTECAN; MATUZUMAB; OXALIPLATIN; PACLITAXEL; PANITUMUMAB; PLACEBO; UNINDEXED DRUG; VORINOSTAT;

ANGIOGENESIS; APOPTOSIS; CANCER MORTALITY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CARCINOGENESIS; CAUSE OF DEATH; CELL CYCLE G1 PHASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIARRHEA; DISEASE ACTIVITY; DISEASE FREE SURVIVAL; DRUG TARGETING; ESOPHAGUS CANCER; ESOPHAGUS SURGERY; GENE MUTATION; HUMAN; LOWER ESOPHAGUS SPHINCTER; METASTASIS POTENTIAL; MONOTHERAPY; MULTIMODALITY CANCER THERAPY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; RASH; REVIEW; TREATMENT FAILURE; TREATMENT OUTCOME;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CYCLIN-DEPENDENT KINASES; DNA MODIFICATION METHYLASES; ENZYME INHIBITORS; ESOPHAGEAL NEOPLASMS; HISTONE DEACETYLASES; HUMANS; METALLOENDOPEPTIDASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 34548234507     PISSN: 11208694     EISSN: 14422050     Source Type: Journal    
DOI: 10.1111/j.1442-2050.2007.00730.x     Document Type: Review

References (80)

1. Homs M Y, Gaast A, Siersema P D, Steyerberg E W, Kuipers E J. Chemotherapy for metastatic carcinoma of the esophagus and gastro-esophageal junction. Cochrane Database Syst Rev 2006; CD004063.
2. Ajani J A, Ilson D H, Daugherty K, Pazdur R, Lynch P M, Kelsen D P. Activity of taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus. J Natl Cancer Inst 1994; 86: 1086-91.
3. Ilson D H, Saltz L, Enzinger P et al. Phase II trial of weekly irinotecan plus cisplatin in advanced esophageal cancer. J Clin Oncol 1999; 17: 3270-5.
4. Mauer A M, Kraut E H, Krauss S A et al. Phase II trial of oxaliplatin, leucovorin and fluorouracil in patients with advanced carcinoma of the esophagus. Ann Oncol 2005; 16: 1320-5.
5. Van Cutsem E, Moiseyenko V M, Tjulandin S et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: A report of the V325 Study Group. J Clin Oncol 2006; 24: 4991-7.
6. Hsu C H, Cheng A L, Hsu C et al. A phase II study of weekly methotrexate, cisplatin, and 24-hour infusion of high-dose 5-fluorouracil and leucovorin (MP-HDFL) in patients with metastatic and recurrent esophageal cancer-improving toxicity profile by infusional schedule and double biochemical modulation of 5-fluorouracil. Anticancer Res 2002; 22: 3621-7.
7. Lin C C, Yeh K H, Yang C H et al. Multifractioned paclitaxel and cisplatin combined with 5-fluorouacil and leucovorin in patients of metastatic or recurrent esophageal squamous cell carcinoma. Anticancer Drugs 2007; 18: In press.
8. Hanawa M, Suzuki S, Dobashi Y et al. EGFR protein overexpression and gene amplification in squamous cell carcinomas of the esophagus. Int J Cancer 2006; 118: 1173-80.
9. Rowinsky E K. The erbB family: Targets for therapeutic development against cancer and therapeutic strategies using monoclonal antibodies and tyrosine kinase inhibitors. Annu Rev Med 2004; 55: 433-57.
10. Shepherd F A, Rodrigues P J, Ciuleanu T et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005; 353: 123-32.
11. Thatcher N, Chang A, Parikh P et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: Results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005; 366: 1527-37.
12. Guo M, Liu S, Lu F. Gefitinib-sensitizing mutations in esophageal carcinoma. N Engl J Med 2006; 354: 2193-4.
13. Kwak E L, Jankowski J, Thayer S P et al. Epidermal growth factor receptor kinase domain mutations in esophageal and pancreatic adenocarcinomas. Clin Cancer Res 2006; 12: 4283-7.
14. Sudo T, Mimori K, Nagahara H et al. Identification of EGFR mutations in esophageal cancer. Eur J Surg Oncol 2007; 33: 44-8.
15. Puhringer-Oppermann F A, Stein H J, Sarbia M. Lack of EGFR gene mutations in exons 19 and 21 in esophageal (Barrett's) adenocarcinomas. Dis Esophagus 2007; 20: 9-11.
16. Janmaat M L, Gallegos-Ruiz M I, Rodriguez J A et al. Predictive factors for outcome in a phase II study of gefitinib in second-line treatment of advanced esophageal cancer patients. J Clin Oncol 2006; 24: 1612-9.
17. Dragovich T, McCoy S, Fenoglio-Preiser C M et al. Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127. J Clin Oncol 2006; 24: 4922-7.
18. Riely G J, Politi K A, Miller V A, Pao W. Update on epidermal growth factor receptor mutations in non-small cell lung cancer. Clin Cancer Res 2006; 12: 7232-41.
19. Blackhall F, Ranson M, Thatcher N. Where next for gefitinib in patients with lung cancer? Lancet Oncol 2006; 7: 499-507.
20. Ferry D R, Anderson M, Beddows K, Mayer P, Price L, Jankowski J. Phase II trial of gefitinib (ZD1839) in advanced adenocarcinoma of the oesophagus incorporating biopsy before and after gefitinib. J Clin Oncol (Meeting Abstracts) 2004; 22: 4021.
21. Adelstein D J, Rybicki L A, Carroll M A, Rice T W, Mekhail T. Phase II trial of gefitinib for recurrent or metastatic esophageal or gastroesophageal junction (GEJ) cancer. J Clin Oncol (Meeting Abstracts) 2005; 23: 4054.
22. Tew W P, Shah M, Schwartz G et al. Phase II trial of erlotinib for second-line treatment in advanced esophageal cancer. Proc Am Soc Clin Oncol GI Cancers Symposium 2005; 23: 5a.
23. Cunningham D, Humblet Y, Siena S et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351: 337-45.
24. Bonner J A, Harari P M, Giralt J et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006; 354: 567-78.
25. Foon K A, Yang X D, Weiner L M et al. Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody. Int J Radiat Oncol Biol Phys 2004; 58: 984-90.
26. Vanhoefer U, Tewes M, Rojo F et al. Phase I study of the humanized antiepidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptor. J Clin Oncol 2004; 22: 175-84.
27. Reid A, Vidal L, Shaw H, de Bono J. Dual inhibition of ErbB1 (EGFR/HER1) and ErbB2 (HER2/neu). Eur J Cancer 2007; 43: 481-9. Epub 8 Jan 2007.
28. Geyer C E, Forster J, Lindquist D et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006; 355: 2733-43.
29. Rowinsky E K. Targeting the molecular target of rapamycin (mTOR). Curr Opin Oncol 2004; 16: 564-75.
30. Appels N M, Beijnen J H, Schellens J H. Development of farnesyl transferase inhibitors: A review. Oncologist 2005; 10: 565-78.
31. Hoshino I, Matsubara H, Hanari N et al. Histone deacetylase inhibitor FK228 activates tumor suppressor Prdx1 with apoptosis induction in esophageal cancer cells. Clin Cancer Res 2005; 11: 7945-52.
32. Kelly W K, Marks P A. Drug insight: Histone deacetylase inhibitors - development of the new targeted anticancer agent suberoylanilide hydroxamic acid. Nat Clin Pract Oncol 2005; 2: 150-7.
33. Duvic M, Talpur R, Ni X et al. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 2007; 109: 31-9.
34. Silverman L R, Demakos E P, Peterson B L et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: A study of the cancer and leukemia group B. J Clin Oncol 2002; 20: 2429-40.
35. Kantarjian H, Issa J P, Rosenfeld C S et al. Decitabine improves patient outcomes in myelodysplastic syndromes: Results of a phase III randomized study. Cancer 2006; 106: 1794-803.
36. Schrump D S, Fischette M R, Nguyen D M et al. Phase I study of decitabine-mediated gene expression in patients with cancers involving the lungs, esophagus, or pleura. Clin Cancer Res 2006; 12: 5777-85.
37. Guner D, Sturm I, Hemmati P et al. Multigene analysis of Rb pathway and apoptosis control in esophageal squamous cell carcinoma identifies patients with good prognosis. Int J Cancer 2003; 103: 445-54.
38. Warner S L, Gray P J, Von Hoff D D. Tubulin-associated drug targets: Aurora kinases, Polo-like kinases, and others. Semin Oncol 2006; 33: 436-48.
39. Benson C, Kaye S, Workman P, Garrett M, Walton M, de Bono J. Clinical anticancer drug development: Targeting the cyclin-dependent kinases. Br J Cancer 2005; 92: 7-12.
40. Senderowicz A M, Headlee D, Stinson S F et al. Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms. J Clin Oncol 1998; 16: 2986-99.
41. Thomas J P, Tutsch K D, Cleary J F et al. Phase I clinical and pharmacokinetic trial of the cyclin-dependent kinase inhibitor flavopiridol. Cancer Chemother Pharmacol 2002; 50: 465-72.
42. Tan A R, Headlee D, Messmann R et al. Phase I clinical and pharmacokinetic study of flavopiridol administered as a daily 1-hour infusion in patients with advanced neoplasms. J Clin Oncol 2002; 20: 4074-82.
43. Shah M A, Kortmansky J, Gonen M et al. A phase I study of weekly irinotecan (CPT), cisplatin (CIS) and flavopiridol (F). J Clin Oncol (Meeting Abstracts) 2004; 22: 4027.
44. Rathkopf D, Fornier M, Shah M A et al. A phase I clinical and pharmacokinetic study of weekly docetaxel followed by flavopiridol: promising activity in metastatic pancreatic cancer. J Clin Oncol (Meeting Abstracts) 2005; 23: 4096.
45. Schwartz G K, O'Reilly E, Ilson D et al. Phase I study of the cyclin-dependent kinase inhibitor flavopiridol in combination with paclitaxel in patients with advanced solid tumors. J Clin Oncol 2002; 20: 2157-70.
46. Shah M A, Schwartz G K. Treatment of metastatic esophagus and gastric cancer. Semin Oncol 2004; 31: 574-87.
47. Shah M A, Kortmansky J, Motwani M et al. A phase I clinical trial of the sequential combination of irinotecan followed by flavopiridol. Clin Cancer Res 2005; 11: 3836-45.
48. Ajani J A, Jiang Y, Faust J et al. A multi-center phase II study of sequential paclitaxel and bryostatin-1 (NSC 339555) in patients with untreated, advanced gastric or gastroesophageal junction adenocarcinoma. Invest New Drugs 2006; 24: 353-7.
49. Papadopoulos K. Targeting the Bcl-2 family in cancer therapy. Semin Oncol 2006; 33: 449-56.
50. Rowinsky E K. Targeted induction of apoptosis in cancer management: The emerging role of tumor necrosis factor-related apoptosis-inducing ligand receptor activating agents. J Clin Oncol 2005; 23: 9394-407.
51. Younes M, Georgakis G V, Rahmani M, Beer D, Younes A. Functional expression of TRAIL receptors TRAIL-R1 and TRAIL-R2 in esophageal adenocarcinoma. Eur J Cancer 2006; 42: 542-7.
52. Tolcher A W, Mita M, Patnaik A et al. A phase I and pharmacokinetic study of HGS-ETR1 (TRM-1), a human monoclonal agonist-antibody to TRAIL R1, in patients with advanced solid tumors. J Clin Oncol (Meeting Abstracts) 2004; 22: 3060.
53. Hotte S J, Hirte H W, Chen E X et al. HGS-ETR1, a fully human monoclonal antibody to the tumor necrosis factor-related apoptosis-inducing ligand death receptor 1 (TRAIL-R1) in patients with advanced solid cancer: results of a phase 1 trial. J Clin Oncol (Meeting Abstracts) 2005; 23: 3052.
54. Pacey S, Plummer R E, Attard G et al. Phase I and pharmacokinetic study of HGS-ETR2, a human monoclonal antibody to TRAIL R2, in patients with advanced solid malignancies. J Clin Oncol (Meeting Abstracts) 2005; 23: 3055.
55. Patnaik A, Wakelee H, Mita M et al. HGS-ETR2 -A fully human monoclonal antibody to TRAIL-R2: Results of a phase I trial in patients with advanced solid tumors. J Clin Oncol (Meeting Abstracts) 2006; 24: 3012.
56. Altieri D C. Targeted therapy by disabling crossroad signaling networks: the survivin paradigm. Mol Cancer Ther 2006; 5: 478-82.
57. Grabowski P, Kuhnel T, Muhr-Wilkenshoff F et al. Prognostic value of nuclear survivin expression in oesophageal squamous cell carcinoma. Br J Cancer 2003; 88: 115-9.
58. Ikeguchi M, Kaibara N. Survivin messenger RNA expression is a good prognostic biomarker for oesophageal carcinoma. Br J Cancer 2002; 87: 883-7.
59. Rosato A, Pivetta M, Parenti A et al. Survivin in esophageal cancer: An accurate prognostic marker for squamous cell carcinoma but not adenocarcinoma. Int J Cancer 2006; 119: 1717-22.
60. Mega S, Miyamoto M, Li L et al. Immunohistochemical analysis of nuclear survivin expression in esophageal squamous cell carcinoma. Dis Esophagus 2006; 19: 355-9.
61. Tolcher A W, Antonia S, Lewis L D et al. A phase I study of YM155, a novel survivin suppressant, administered by 168 hour continuous infusion to patients with advanced solid tumors. J Clin Oncol (Meeting Abstracts) 2006; 24: 3014.
62. Richardson P G, Sonneveld P, Schuster M W et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005; 352: 2487-98.
63. Izzo J G, Malhotra U, Wu T T et al. Association of activated transcription factor nuclear factor kappab with chemoradiation resistance and poor outcome in esophageal carcinoma. J Clin Oncol 2006; 24: 748-54.
64. Izzo J G, Correa A M, Wu T T et al. Pretherapy nuclear factor-kappaB status, chemoradiation resistance, and metastatic progression in esophageal carcinoma. Mol Cancer Ther 2006; 5: 2844-50.
65. Vallbohmer D, Lenz H J. Predictive and prognostic molecular markers in outcome of esophageal cancer. Dis Esophagus 2006; 19: 425-32.
66. Overall C M, Kleifeld O. Tumour microenvironment -opinion: Validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nat Rev Cancer 2006; 6: 227-39.
67. Bramhall S R, Hallissey M T, Whiting J et al. Marimastat as maintenance therapy for patients with advanced gastric cancer: A randomised trial. Br J Cancer 2002; 86: 1864-70.
68. Cooney M M, van Heeckeren W, Bhakta S, Ortiz J, Remick S C. Drug insight: Vascular disrupting agents and angiogenesis -novel approaches for drug delivery. Nat Clin Pract Oncol 2006; 3: 682-92.
69. Gerber H P, Ferrara N. Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res 2005; 65: 671-80.
70. Kleespies A, Guba M, Jauch K W, Bruns C J. Vascular endothelial growth factor in esophageal cancer. J Surg Oncol 2004; 87: 95-104.
71. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-42.
72. Sandler A, Gray R, Perry M C et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355: 2542-50.
73. Gordon M S, Margolin K, Talpaz M et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 2001; 19: 843-50.
74. Shah M A, Ramanathan R K, Ilson D H et al. Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol 2006; 24: 5201-6.
75. Enzinger P C, Fedias P, Meyerhardt J et al. Phase II bevacizumab and docetaxelt in metastatic esophageal and gastric cancer. Proc of the Am Soc Clin Oncol GI Cancers Symposium 2006; 24: (Abstr 68).
76. Demetri G D, van Oosterom A T, Garrett C R et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: A randomised controlled trial. Lancet 2006; 368: 1329-38.
77. Escudier B, Eisen T, Stadler W M et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356: 125-34.
78. Motzer R J, Hutson T E, Tomczak P et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356: 115-24.
79. Strumberg D, Awada A, Hirte H et al. Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced solid tumours: is rash associated with treatment outcome? Eur J Cancer 2006; 42: 548-56.
80. Faivre S, Delbaldo C, Vera K et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 2006; 24: 25-35.